TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1477-1487

  Moretti, Erica ^a   Desmedt, Christine ^b   Biagioni, Chiara ^a   Regan, Meredith M ^c   Oakman, Catherine ^a   Larsimont, Denis ^b   Galardi, Francesca ^a   Piccart Gebhart, Martine ^b   Sotiriou, Christos ^b   Rimm, David L ^d   Di Leo, Angelo ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b JULES BORDET INSTITUTE   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anthracyclines; biomarker; breast cancer; quantitative immunofluorescence; TOP2A

Indexed keywords

CYTOPLASM PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; TOP2A PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CELLULAR DISTRIBUTION; GENE AMPLIFICATION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; PROGNOSIS; PROTEIN TRANSPORT; TOPOISOMERASE II INHIBITORS;

EID: 84885635917     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.103     Document Type: Article

References (42)

1. Smith PJ, Soues S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br. J. Cancer 70, S47-S51 (1994 (Pubitemid 24275539)
2. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354(20), 2103-2111 (2006 (Pubitemid 43736610)
3. De Laurentiis M, Caputo F, Massarelli E et al. HER2 expression and anthracyclines effect: results from the Naples GUN3 randomised trial. Proc. Am. Soc. Clin. Oncol. 20, Abstract 133 (2001
4. Paik S, Bryant J, Park C et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl Cancer Inst. 90(18), 1361-1370 (1998 (Pubitemid 28439960)
5. Di Leo A, Gancberg D, Larsimont D. HER-2 amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 8(5), 1107-1116 (2002 (Pubitemid 34517647)
6. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23(30), 7483-7490 (2005 (Pubitemid 46291811)
7. Moliterni A, Ménard S, Valagussa P et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J. Clin. Oncol. 21(3), 458-462 (2003 (Pubitemid 46606475)
8. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl Cancer Inst. 92(24), 1991-1998 (2000 (Pubitemid 32045895)
9. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl Cancer Inst. 100(1), 14-20 (2008). Demonstrates the additional benefit from inclusion of anthracyclines in adjuvant therapy in HER2-positive patients only. (Pubitemid 351767337)
10. Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res. Treat. 109(2), 209-229 (2008
11. Ejlertsen B, Jensen MB, Nielsen KV et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J. Clin. Oncol. 28(6), 984-990 (2010
12. Farmer P, Bonnefoi H, Anderle P et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15(1), 68-74 (2009
13. Burgess DJ, Doles J, Zender L et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl Acad. Sci. USA 105(26), 9053-9058 (2008
14. O'Malley FP, Chia S, Tu D et al. Topoisomerase IIa and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl Cancer Inst. 101(9), 644-650 (2009
15. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24(16), 2428-2436 (2006 (Pubitemid 46630618)
16. Desmedt C, Di Leo A, de Azambuja E et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29(12), 1578-1586 (2011
17. Gunnarsdóttir KA, Jensen MB, Zahrieh D et al. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) (stepp) analysis on danish breast cancer cooperative group study 89d Breast Cancer Res. Treat 2010 1231 163-169
18. Di Leo A, Desmedt C, Bartlett JM et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 12(12), 1134-1142 (2011). Findings from this large meta-analysis of five adjuvant trials do not support the restriction of anthracycline use to patients with HER2-amplified or TOP2A-aberrated tumors.
19. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14(16), 5158-5165 (2008
20. Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J. Clin. Oncol. 26(31), 5027-5035 (2008
21. O'Malley FP, Chia S, Tu D et al. Topoisomerase IIa protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res. Treat. 128(2), 401-409 (2011
22. Durbecq V, Paesmans M, Cardoso F et al. Topoisomerase-IIa expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol. Cancer Ther. 3(10), 1207-1214 (2004 (Pubitemid 39440165)
23. Gestevez L, Fortes JL, Adrover E et al. Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM Phase II study. Clin. Transl. Oncol. 11(1), 54-59 (2009
24. Fritz P, Cabrera CM, Dippon J et al. c-erbB2 and topoisomerase IIa protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res. 7(3), R374-R384 (2005
25. Durbecq V, Desmedt C, Paesmans M et al. Correlation between topoisomerase-IIa gene amplification and protein expression in HER-2 amplified breast cancer. Int. J. Oncol. 25(5), 1473-1479 (2004
26. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase IIa protein in human breast tumor samples. Genes Chromosome Cancer 39(4), 288-297 (2004 (Pubitemid 38326310)
27. Callagy G, Pharoah P, Chin SF et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J. Pathol. 205(3), 388-396 (2005 (Pubitemid 40253928)
28. Brase JC, Schmidt M, Fischbach T et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin. Cancer Res. 16(8), 2391-2401 (2010).
29. Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D. Topoisomerase IIa as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur. J. Cancer 44(18), 2791-2798 (2008
30. Klijn JG, Berns PM, Bontenbal M, Foekens JA. Growth factors. Clinical implications in breast cancer. Ann. N.Y. Acad. Sci. 698, 85-101 (1993 (Pubitemid 24027627)
31. Vincent-Salomon A, Rousseau A, Jouve M et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur. J. Cancer 40(10), 1502-1508 (2004 (Pubitemid 38757737)
32. Bartlett JM, Munro AF, Dunn JA et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 11(3), 266-274 (2010). Important results that conflict with many other trials and do not favor HER2, TOP2A or Ki67 as predictive tools for anthracycline use.
33. Oloumi A, MacPhail SH, Johnston PJ, Banáth JP, Olive PL. Changes in subcellular distribution of topoisomerase IIa correlate with etoposide resistance in multicell spheroid and xenograft tumours. Cancer Res. 60(20), 5747-5753 (2000
34. Ernst AI, Soltermann A, Sigrist JA, Widmer L, Gasser SM, Stahel RA. Ectopic expression of human topoisomerase IIa fragments and etoposide resistance in mammalian cells. Int. J. Cancer 88(1), 99-107 (2000
35. Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIa correlates with etoposide resistance in human myeloma cells. Exp. Cell Res. 295(2), 421-431 (2004 (Pubitemid 38490496)
36. Turner JG, Marchion DC, Dawson JL et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 69(17), 6899-6905 (2009
37. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8(11), 1323-1327 (2002 (Pubitemid 35373567)
38. Gustavson MD, Molinaro AM, Tedeschi G, Camp RL, Rimm DL. AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Arch. Pathol. Lab Med. 132(11), 1746-1752 (2008
39. Andre F, Conforti R, Moeder CB et al. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Ann. Oncol. 23(8), 2059-2064 (2012
40. Moeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, fluorescence-based in situ assessment of protein expression. Methods Mol. Biol. 520, 163-175 (2009
41. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab. Invest. 87(7), 662-669 (2007 (Pubitemid 46920099)
42. Nasir A, Chen DT, Gruidl M et al. Novel molecular markers of malignancy in histologically normal and benign breast. Patholog. Res. Int. 2011, 489064 (2011).